Sex and ethnic disparities in hepatitis B evaluation and treatment across the world
Sahith Kudaravalli,Daniel Q Huang,Ming-Lun Yeh,Lindsey Trinh,P C Tsai,Yao-Chun Hsu,Leslie Y Kam,Vy H Nguyen,Eiichi Ogawa,Dong Hyun Lee,Takanori Ito,Tsunamasa Watanabe,Masaru Enomoto,Carmen Monica Preda,Michael K L Ko,Rex Wan-Hin Hui,Masanori Atsukawa,Takanori Suzuki,Sebastian Marciano,Ana Barreira,Son Do,Haruki Uojima,Hirokazu Takahashi,Sabrina X Z Quek,Htet Htet Toe Wai Khine,Masatoshi Ishigami,Norio Itokawa,Min Seok Go,Ritsuzo Kozuka,Raluca Ioana Marin,Irina Sandra,Jiayi Li,Jian Q Zhang,Christopher Wong,Yoko Yoshimaru,Dang K H Vo,Cheng-Hao Tseng,Chul-Jin Lee,Kaori Inoue,Mayumi Maeda,Joseph K Hoang,Angela Chau,Wan-Long Chuang,Chia-Yen Dai,Jee-Fu Huang,Chung-Feng Huang,Maria Buti,Yasuhito Tanaka,Adrian Carlos Gadano,Man-Fung Yuen,Ramsey Cheung,Seng Gee Lim,Huy N Trinh,Hidenori Toyoda,Ming-Lung Yu,Mindie H Nguyen
DOI: https://doi.org/10.1016/j.jhep.2024.02.033
Abstract:Background & aims: Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of evaluation and treatment in patients from the REAL-B consortium. Methods: This was a cross-sectional study nested within our retrospective multinational clinical consortium (2000-2021). We determined the proportions of patients receiving adequate evaluation, meeting AASLD treatment criteria, and initiating treatment at any time during the study period. We also identified factors associated with receiving adequate evaluation and treatment using multivariable logistic regression analyses. Results: We analyzed 12,566 adult treatment-naïve patients with CHB from 25 centers in 9 countries (mean age 47.1 years, 41.7% female, 96.1% Asian, 49.6% Western region, 8.7% cirrhosis). Overall, 73.3% (9,206 patients) received adequate evaluation. Among the adequately evaluated, 32.6% (3,001 patients) were treatment eligible by AASLD criteria, 83.3% (2,500 patients) of whom were initiated on NAs, with consistent findings in analyses using EASL criteria. On multivariable logistic regression adjusting for age, sex, cirrhosis, and ethnicity plus region, female sex was associated with adequate evaluation (adjusted odds ratio [aOR] 1.13, p = 0.004), but female treatment-eligible patients were about 50% less likely to initiate NAs (aOR 0.54, p <0.001). Additionally, the lowest evaluation and treatment rates were among Asian patients from the West, but no difference was observed between non-Asian patients and Asian patients from the East. Asian patients from the West (vs. East) were about 40-50% less likely to undergo adequate evaluation (aOR 0.60) and initiate NAs (aOR 0.54) (both p <0.001). Conclusions: Evaluation and treatment rates were suboptimal for patients with CHB in both the East and West, with significant sex and ethnic disparities. Improved linkage to care with linguistically competent and culturally sensitive approaches is needed. Impact and implications: Significant sex and ethnic disparities exist in hepatitis B evaluation and treatment, with female treatment-eligible patients about 50% less likely to receive antiviral treatment and Asian patients from Western regions also about 50% less likely to receive adequate evaluation or treatment compared to Asians from the East (there was no significant difference between Asian patients from the East and non-Asian patients). Improved linkage to care with linguistically competent and culturally sensitive approaches is needed.